271 related articles for article (PubMed ID: 12901973)
1. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.
Akin C; Brockow K; D'Ambrosio C; Kirshenbaum AS; Ma Y; Longley BJ; Metcalfe DD
Exp Hematol; 2003 Aug; 31(8):686-92. PubMed ID: 12901973
[TBL] [Abstract][Full Text] [Related]
2. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
Verstovsek S; Akin C; Manshouri T; Quintás-Cardama A; Huynh L; Manley P; Tefferi A; Cortes J; Giles FJ; Kantarjian H
Leuk Res; 2006 Nov; 30(11):1365-70. PubMed ID: 16797704
[TBL] [Abstract][Full Text] [Related]
3. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.
Ma Y; Zeng S; Metcalfe DD; Akin C; Dimitrijevic S; Butterfield JH; McMahon G; Longley BJ
Blood; 2002 Mar; 99(5):1741-4. PubMed ID: 11861291
[TBL] [Abstract][Full Text] [Related]
4. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
Zermati Y; De Sepulveda P; Féger F; Létard S; Kersual J; Castéran N; Gorochov G; Dy M; Ribadeau Dumas A; Dorgham K; Parizot C; Bieche Y; Vidaud M; Lortholary O; Arock M; Hermine O; Dubreuil P
Oncogene; 2003 Feb; 22(5):660-4. PubMed ID: 12569358
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
6. STI571 inhibits growth and adhesion of human mast cells in culture.
Takeuchi K; Koike K; Kamijo T; Ishida S; Nakazawa Y; Kurokawa Y; Sakashita K; Kinoshita T; Matsuzawa S; Shiohara M; Yamashita T; Nakajima M; Komiyama A
J Leukoc Biol; 2003 Dec; 74(6):1026-34. PubMed ID: 12960256
[TBL] [Abstract][Full Text] [Related]
7. Influence of the tyrosine kinase inhibitors STI571 (Glivec), lavendustin A and genistein on human mast cell line (HMC-1(560)) activation.
Löber K; Alfonso A; Escribano L; Botana LM
J Cell Biochem; 2008 Mar; 103(4):1076-88. PubMed ID: 17661356
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.
Ueda S; Ikeda H; Mizuki M; Ishiko J; Matsumura I; Tanaka H; Shibayama H; Sugahara H; Takai E; Zhang X; Machii T; Kanakura Y
Int J Hematol; 2002 Dec; 76(5):427-35. PubMed ID: 12512837
[TBL] [Abstract][Full Text] [Related]
9. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
10. [In vitro effect of STI571 on expression of c-kit in bone marrow cells from patients with acute non-lymphocytic leukemia].
Tan Tai LF; Yi ZS; Feng R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):256-8. PubMed ID: 12844407
[TBL] [Abstract][Full Text] [Related]
11. KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.
Lee YN; Brandal S; Noel P; Wentzel E; Mendell JT; McDevitt MA; Kapur R; Carter M; Metcalfe DD; Takemoto CM
Blood; 2011 Mar; 117(13):3629-40. PubMed ID: 21273305
[TBL] [Abstract][Full Text] [Related]
12. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
[TBL] [Abstract][Full Text] [Related]
13. Mastocytosis: advances in diagnosis and treatment.
Hungness SI; Akin C
Curr Allergy Asthma Rep; 2007 Jul; 7(4):248-54. PubMed ID: 17547845
[TBL] [Abstract][Full Text] [Related]
14. C-Kit controls IL-1β-induced effector functions in HMC-cells.
Drube S; Schmitz F; Göpfert C; Weber F; Kamradt T
Eur J Pharmacol; 2012 Jan; 675(1-3):57-62. PubMed ID: 22173128
[TBL] [Abstract][Full Text] [Related]
15. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
[TBL] [Abstract][Full Text] [Related]
16. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
Frost MJ; Ferrao PT; Hughes TP; Ashman LK
Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
[TBL] [Abstract][Full Text] [Related]
18. STI571 (Glivec) affects histamine release and intracellular pH after alkalinisation in HMC-1560, 816.
Löber K; Alfonso A; Escribano L; Botana LM
J Cell Biochem; 2008 Feb; 103(3):865-76. PubMed ID: 17615556
[TBL] [Abstract][Full Text] [Related]
19. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
20. The stem cell factor-c-kit system and mast cells in human pancreatic cancer.
Esposito I; Kleeff J; Bischoff SC; Fischer L; Collecchi P; Iorio M; Bevilacqua G; Büchler MW; Friess H
Lab Invest; 2002 Nov; 82(11):1481-92. PubMed ID: 12429808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]